2020 News

04.01.2020 Information

Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)

03.25.2020 Press Release

Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication

03.24.2020 Information

Santen's Measures To Combat Novel Coronavirus (COVID-19) Infections

03.13.2020 Press Release

Notice of Corporate Officer Appointments

03.10.2020 Press Release

Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration

03.05.2020 Press Release

Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)

02.27.2020 Information

Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.

02.18.2020 Press Release

Notice of personnel change

02.04.2020 Press Release

Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices

02.04.2020 Press Release

Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance

01.23.2020 Press Release

Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!

01.10.2020 Press Release

Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology

01.06.2020 Press Release

Santen Announces the Construction of China Second Plant